ArticleBMJ open2023

Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol.

Lucy Vivash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.